Arecor Limited

AT247, a novel formulation of insulin with an ultra-rapid glucose lowering action, can transform diabetes care by enabling the development of a fully closed loop artificial pancreas (AP) system. The AT247 formulation was developed using Arecor's proprietary formulation technology and is based on a unique mixture of two ingredients. The first results in si...

no public description

There is a recognised unmet medical need to develop insulin products with a significantly faster onset of action compared with the current state-of-the-art prandial insulin products (Novolog, Humalog, Fiasp). Prandial insulin is used by diabetics to control blood glucose rises after meals. To ensure effective blood glucose management and the best patient ...

There is an unmet need to develop advanced therapies that combine two or more therapeutic products in one dose to improve patient convenience. This leads to better compliance, improved health outcomes and a better patient experience. However, it is often impossible to develop these co-formulations due to very different formulation conditions required to s...

Arecor is a world leader in developing stable formulations of therapeutics, with in-house development programmes aimed at differentiated product concepts in diabetes. Arecor has solid plans for developing those product concepts to Phase I clinical proof-of-concept and subsequent licensing of the assets. One of the product concepts is liquid glucagon, both...

Availability of low cost insulin products, particularly products that can be distributed and used outside the cold chain is critical to developing an effective healthcare system that can deal with the rapidly increasing incidence of diabetes. This project will combine the expertise and technologies of Arecor and Cadila Pharmaceuticals to develop a innovat...

This project represents a unique opportunity to translate British technology and expertise from the human health sector into livestock disease control in the developing world context. The project focuses on East Coast Fever (ECF), a major constraint on small-holder cattle production in East, Central and Southern Africa. An effective vaccine, ECF-ITM, curr...

The aim of the project is to use innovative formulation technology to develop a proof-ofconcept for insulin product with a consistent, ultra-long release profile. Formulations will first be validated with the use of an in vitro model before demonstrating the ultra-long release profile in a relevant animal model. Arecor is a biotherapeutic formulation comp...

The aim of this project is to provide new formulations that bring about a step change in biopharmaceutical yield and quality by improving product stability through the most protein degradation sensitive/impactful areas of downstream processing (DSP). This is a novel approach to improving process efficiency as currently protein products have comparatively ...

A growing number of drugs that are being developed to combat infection and disease are protein based "biotherapeutics". The supply of these vital biotherapeutics is limited only to areas where there is a sufficient cold-chain i.e. fridges/freezers. Arecor is a biotherapeutic formulation company that has developed technology to stabilise liquid formulation...

The 3 human influenza pandemics in the 20th century killed tens of millions of people worldwide. Sporadic human infections by avian H5N1 virus in the past few years have led the scientific community to believe that a virulent virus may emerge as the result of re-assortment between H5N1 virus and seasonal influenza virus, causing another pandemic. There is...

Drug formulation has the power to move a product from a hospital setting directly to the home, empowering the patient to control their own treatment. High concentration formulations of antibodies have the potential to shift the burden of outpatient intravenous infusions in the clinic to the use of a ready-to-use autoinjector. Novel chemicals designed at A...